Background: Published data on HIV, HBV, and HCV in correctional facilities in Nigeria is scarce. We set out to establish the seroprevalence, co-infection, and risk factors for these infections for the first time among prison inmates in Nasarawa State, Nigeria. Methodology: In a cross-sectional study conducted between April and May, 2007, blood samples were collected from 300 male prisoners of a mean age of 29.2 years, in the state’s four medium-security prisons (overall population: 587). Prior to the study, ethical clearance and informed consent were obtained and structured questionnaires were administered. Samples were analyzed for HIV, HBsAg, and HCV using anti-HIV 1+2-EIA-avicenna, ShantestTM-HBsAg ELISA, and anti-HCV-EIA-avicenna, respectively. Specimens initially reactive for HIV were retested with vironostika microelisa. Data were analyzed using SPSS version 13.0. P values ≤ 0.05 were considered significant. Results: Of the 300 subjects, 54 (18.0 %), 69 (23.0 %), and 37 (12.3 %) tested positive for HIV, HBV, and HCV, respectively. Co-infections were eight (2.7 %) for HIV/HBV and two (0.7 %) for HBV/HCV. Those aged 21-26 years were more likely to be infected with HIV and HBV, while those aged 33-38 years had the highest HCV infection. Associated risk factors included duration in prison, previous incarceration (for HIV, HBV and HCV), intra-prison anal sex, multiple sex partners (for HIV and HBV), ignorance of transmission modes, blood transfusion, and alcohol consumption (for HBV and HCV). No inmate injected drugs. Conclusions: The overall outcome represents the need for prison-focused intervention initiatives in Nigeria. Injected drug use is an unlikely major transmission mode among Nigerian inmates.

BackgroundA multi-million dollar research initiative involving the National Institutes of Health (NIH), Wellcome Trust and African scientists has been launched. The initiative, referred to as H3Africa, is an acronym that stands for Human Heredity and Health in Africa. Here, we outline what this initiative is set to achieve and the latest commitments of the key players as at October 2013.FindingsThe initiative has so far been awarded over $74 million in research grants. During the first set of awards announced in 2012, the NIH granted $5 million a year for a period of five years, while the Wellcome Trust doled out at least $12 million over the period to the research consortium. This was in addition to Wellcome Trust’s provision of administrative support, scientific consultation and advanced training, all in collaboration with the African Society for Human Genetics. In addition, during the second set of awards announced in October 2013, the NIH awarded to the laudable initiative 10 new grants of up to $17 million over the next four years.ConclusionsH3Africa is poised to transform the face of research in genomics, bioinformatics and health in Africa. The capacity of African scientists will be enhanced through training and the better research facilities that will be acquired. Research collaborations between Africa and the West will grow and all stakeholders, including the funding partners, African scientists, scientists across the globe, physicians and patients will be the eventual winners.

Background: Infection with Herpes Simplex Virus Type-2 (HSV-2) is the primary cause of genital herpes and the most common cause of genital ulcer disease (GUD) worldwide. There is little information on the prevalence of HSV-2 in Nigeria. Methodology: Specimens were collected from 162 volunteers attending Jos University Teaching Hospital and tested for HSV-2 antibodies using HSV-2 Type specific IgG EIA test kit (Globalemed LLC Alexandria VA, USA). Data were analyzed using SPSS version 13.0. P values ≤ 0.05 were considered significant. numbr Results: Out of the 162 individuals tested, 141 (87.0%) were HSV-2 positive. Infected individuals were more likely to be male than female (92.8% versus 86.4%; P > 0.05). There were high rates of infection in all age groups, and the prevalence increased with age. However, multivariate logistic regression analysis showed that HSV-2 prevalence was not significantly associated with increasing age, sex, marital status, occupation, educational status, and number of sex partners (P > 0.05). Conclusions: The results highlight the potential public health impact of HSV-2 in Nigeria where anti-HSV-2 testing is not generally performed in all populations, especially considering the risk of neonatal transmission and the attendant complications at birth.

Over the past few decades, major advances in the field of molecular biology, coupled with advances in genomic technologies, have led to an explosive growth in the biological data generated by the scientific community. The critical need to process and analyze such a deluge of data and turn it into useful knowledge has caused bioinformatics to gain prominence and importance. Bioinformatics is an interdisciplinary research area that applies techniques, methodologies, and tools in computer and information science to solve biological problems. In Nigeria, bioinformatics has recently played a vital role in the advancement of biological sciences. As a developing country, the importance of bioinformatics is rapidly gaining acceptance, and bioinformatics groups comprised of biologists, computer scientists, and computer engineers are being constituted at Nigerian universities and research institutes. In this article, we present an overview of bioinformatics education and research in Nigeria. We also discuss professional societies and academic and research institutions that play central roles in advancing the discipline in Nigeria. Finally, we propose strategies that can bolster bioinformatics education and support from policy makers in Nigeria, with potential positive implications for other developing countries.

No abstract

No abstract

Résumé La maladie du Coronavirus 2019 (Covid-19) va continuer à avoir un impact sérieux sur la façon dont nous vivons pour encore quelques années jusqu’à ce que nous mettions au point et administrions un vaccin. Malheureusement, cela ne va pas être la dernière épidémie à laquelle le monde va être confronté, et la prochaine pourrait avoir des conséquences encore plus désastreuses en Afrique que le Covid-19 à moins que des leçons soient tirées pour un confinement plus rapide et plus sévère. Le syndrome respiratoire aigu coronavirus 2 (Sars-CoV-2), la cause virale du Covid-19, a été introduite, pense-t-on, sur le continent africain par des travailleurs qui revenaient de pays fortement touchés en Asie, Europe et Amérique. Dans une pandémie où la morbidité et la mortalité sont relativement faibles en Afrique, il est alarmant de constater qu'environ cinq mois après la confirmation du premier cas de COVID-19 en Égypte le 14 février 2020, le taux d'infection reste à une phase exponentielle, 47 pays africains ayant déclaré un total de 766.803 cas, 13.191 décès et 486.925 récupérations au 31 juillet 2020 ; Le Nigeria a fait état de 42.689 cas, 878 décès et 19.290 guérisons, l'État de Lagos représentant près de la moitié de tous les cas au Nigeria. Il est important de noter que les leçons tirées de l'épidémie d'Ebola ont eu un impact significatif sur la réponse du Nigeria au COVID-19. Dans cet article, nous examinons la réponse du Nigeria, la préparation du système de santé et les leçons qui sont essentielles pour contenir les futures épidémies ou pandémies de toute maladie infectieuse en Afrique.

Background: In spite of the availability of an effective vaccine since 1982 against hepatitis B, infection with hepatitis B virus (HBV), which is 50 to 100 times more infectious than HIV, still persists in most parts of the world with Nigeria being described as an endemic zone. We therefore set out to establish the prevalence of this infection and evaluate its relationship with age and gender in urban Nigerians. Methodology: During pre-vaccination tests, blood samples were collected by finger-prick and venepuncture from 1,891 subjects aged ≤ 60 years, between 2008 and 2009 after having obtained informed consent and ethical clearance. Smart Check HBsAg (Globalemed, Cape Town, South Africa) and ShantestTM-HBsAg Elisa (Shantha Biotechnics Ltd, Hyderabad, India) were used for initial and confirmatory tests respectively. Results: Of the 1,891 participants, 957 (50.6 %) were males and 934 (49.4%) were females. Overall 114 (6.0%) were positive, of whom 71 (7.4%) were males and 43 (4.6%) females. Those aged 21-30 years had the highest infection rate, and males were more likely to be infected with the virus than females (P > 0.05). Conclusions: Such a high prevalence of a vaccine-preventable infection questions the effectiveness of the Nigerian vaccination strategies. The Nigerian government hepatitis B vaccination programme, which hitherto is limited to the National Childhood Immunisation Programme, should include the adult population.